Key result
Renin-angiotensin system inhibitors did not improve time-to-treatment failure compared to no RASI in patients with cancer treated with VSP inhibitors.
Why the study?
VSP inhibitors often cause hypertension, and while RASIs were suggested to have synergistic effects, their actual impact on clinical outcomes was unknown.
Does renin-angiotensin system inhibitor therapy improve time-to-treatment failure in cancer patients receiving anti-VEGF therapy and antihypertensive treatment?
Cohort (n=2,380)
Does renin-angiotensin system inhibitor therapy improve time-to-treatment failure in cancer patients receiving anti-VEGF therapy and antihypertensive treatment?
Answers are grounded in this paper and cite their sources.
Renin-angiotensin system inhibitors do not provide a synergistic clinical benefit over other antihypertensives for cancer patients developing hypertension from anti-VEGF therapy.
BACKGROUND: Cancer treatment with vascular endothelial growth factor signalling pathway (VSP) inhibitors frequently causes hypertension. Although previous reports suggested that the antihypertensive drug renin-angiotensin system inhibitor (RASI) may have a positive synergistic effect with VSP inhibitors, the actual impact on clinical outcomes is unknown. OBJECTIVES: The study aims to clarify whether RASIs exhibit clinical benefits for patients with cancer with hypertension. METHOD: From the Longevity Improvement and Fair Evidence Study database, comprising Japanese claims data between 2016 and 2020, we reviewed 2380 patients treated with VSP inhibitors who received antihypertensive treatment during cancer therapy. The patients were classified into two groups: with-RASI (n=883) and without-RASI (n=1497). In addition, 1803 of these patients treated for hypertension with RASI-only (n=707) or calcium channel blocker-only (n=1096) were also reviewed. The time-to-treatment failure (TTF), the interval from initiation of chemotherapy to its discontinuation, was applied as the primary endpoint. RESULTS: The median TTFs were 167 (60-382) days in the with-RASI group and 161 (63-377) days in the without-RASI group (p=0.587). All models, including Cox proportional hazard models and multiple propensity score models, did not reveal the superiority of with-RASI treatment. In the propensity score matching model, the HR for treatment with-RASI compared with that for without-RASI was 0.96 (95% CI 0.86 to 1.06, p=0.386). In addition, the TTFs of RASI-only were not superior to calcium channel blocker-only (p=0.584). CONCLUSIONS: RASIs for hypertension do not benefit clinical outcomes during cancer therapy with VSP inhibitors. In addition, RASIs and calcium channel blockers have comparable clinical efficacy as first-line antihypertensive.
No takes yet. Share an insight, caveat, or question.
Moriyama et al. (2022) conducted a cohort in Cancer with hypertension treated with VSP inhibitors (n=2,380). Renin-angiotensin system inhibitors (RASI) vs. Without-RASI was evaluated on Time-to-treatment failure (TTF), the interval from initiation of chemotherapy to its discontinuation (HR 0.96, 95% CI 0.86 to 1.06, p=0.386). Renin-angiotensin system inhibitors did not improve time-to-treatment failure compared to no RASI in patients with cancer treated with VSP inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: